Literature DB >> 11982604

Inflammatory responses in Ebola virus-infected patients.

S Baize1, E M Leroy, A J Georges, M-C Georges-Courbot, M Capron, I Bedjabaga, J Lansoud-Soukate, E Mavoungou.   

Abstract

Ebola virus subtype Zaire (Ebo-Z) induces acute haemorrhagic fever and a 60-80% mortality rate in humans. Inflammatory responses were monitored in victims and survivors of Ebo-Z haemorrhagic fever during two recent outbreaks in Gabon. Survivors were characterized by a transient release in plasma of interleukin-1beta (IL-1beta), IL-6, tumour necrosis factor-alpha (TNFalpha), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta early in the disease, followed by circulation of IL-1 receptor antagonist (IL-1RA) and soluble receptors for TNFalpha (sTNF-R) and IL-6 (sIL-6R) towards the end of the symptomatic phase and after recovery. Fatal infection was associated with moderate levels of TNFalpha and IL-6, and high levels of IL-10, IL-1RA and sTNF-R, in the days before death, while IL-1beta was not detected and MIP-1alpha and MIP-1beta concentrations were similar to those of endemic controls. Simultaneous massive activation of monocytes/macrophages, the main target of Ebo-Z, was suggested in fatal infection by elevated neopterin levels. Thus, presence of IL-1beta and of elevated concentrations of IL-6 in plasma during the symptomatic phase can be used as markers of non-fatal infection, while release of IL-10 and of high levels of neopterin and IL-1RA in plasma as soon as a few days after the disease onset is indicative of a fatal outcome. In conclusion, recovery from Ebo-Z infection is associated with early and well-regulated inflammatory responses, which may be crucial in controlling viral replication and inducing specific immunity. In contrast, defective inflammatory responses and massive monocyte/macrophage activation were associated with fatal outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11982604      PMCID: PMC1906357          DOI: 10.1046/j.1365-2249.2002.01800.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.

Authors:  J A Wilson; M K Hart
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.

Authors:  T W Geisbert; L E Hensley; T R Gibb; K E Steele; N K Jaax; P B Jahrling
Journal:  Lab Invest       Date:  2000-02       Impact factor: 5.662

4.  IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.

Authors:  L Ding; P S Linsley; L Y Huang; R N Germain; E M Shevach
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

5.  Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting.

Authors:  E M Leroy; S Baize; C Y Lu; J B McCormick; A J Georges; M C Georges-Courbot; J Lansoud-Soukate; S P Fisher-Hoch
Journal:  J Med Virol       Date:  2000-04       Impact factor: 2.327

6.  Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

Authors:  M Gupta; S Mahanty; M Bray; R Ahmed; P E Rollin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

8.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

9.  Epitopes involved in antibody-mediated protection from Ebola virus.

Authors:  J A Wilson; M Hevey; R Bakken; S Guest; M Bray; A L Schmaljohn; M K Hart
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

10.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Authors:  M Bray; K Davis; T Geisbert; C Schmaljohn; J Huggins
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

View more
  154 in total

1.  Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus.

Authors:  Hideki Ebihara; Barry Rockx; Andrea Marzi; Friederike Feldmann; Elaine Haddock; Douglas Brining; Rachel A LaCasse; Don Gardner; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 2.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

3.  Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.

Authors:  Victoria M Wahl-Jensen; Tatiana A Afanasieva; Jochen Seebach; Ute Ströher; Heinz Feldmann; Hans-Joachim Schnittler
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

6.  Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome.

Authors:  Anita K McElroy; Bobbie R Erickson; Timothy D Flietstra; Pierre E Rollin; Stuart T Nichol; Jonathan S Towner; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2014-02-12       Impact factor: 5.226

7.  Food Insecurity as a Risk Factor for Outcomes Related to Ebola Virus Disease in Kono District, Sierra Leone: A Cross-Sectional Study.

Authors:  J Daniel Kelly; Eugene T Richardson; Michael Drasher; M Bailor Barrie; Sahr Karku; Mohamed Kamara; Katrina Hann; Kerry Dierberg; Allan Hubbard; Christina P Lindan; Paul E Farmer; George W Rutherford; Sheri D Weiser
Journal:  Am J Trop Med Hyg       Date:  2018-03-15       Impact factor: 2.345

8.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

9.  Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Authors:  Lauren M Smith; Lisa E Hensley; Thomas W Geisbert; Joshua Johnson; Andrea Stossel; Anna Honko; Judy Y Yen; Joan Geisbert; Jason Paragas; Elizabeth Fritz; Gene Olinger; Howard A Young; Kathleen H Rubins; Christopher L Karp
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

10.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.